{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-001518","form_type":"8-K","ticker":"HBIO","cik":"0001123494","company_name":"HARVARD BIOSCIENCE INC","filed_at":"2023-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.921783+00:00","generated_at":"2026-06-18T06:22:37.676411+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"HBIO Q4 revenue $28.4M (-14% YoY), GAAP net loss $1.7M; guides low-single-digit growth in FY23","bullets":["Revenues $28.4M, down 14% YoY; negative currency impact of $1.0M.","GAAP operating loss $0.5M vs income $1.7M; GAAP diluted EPS -$0.04 vs $0.02.","Adjusted EPS $0.04 vs $0.08; adjusted EBITDA $3.7M vs $5.7M.","FY23 guidance: low-to-mid single-digit revenue growth, improving gross margin, adjusted EBITDA expansion.","Plans to reduce leverage ratio to ~2x by year end with improved margins and working capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-001518","json":"https://secwatch.observer/filing/0001171843-23-001518.json","markdown":"https://secwatch.observer/filing/0001171843-23-001518.md","text":"https://secwatch.observer/filing/0001171843-23-001518.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1123494/000117184323001518/0001171843-23-001518-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1123494/000117184323001518/f8k_030923.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T06:22:37.676411+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2b6193aae468e619616a937ca2bc1992e2adeaf6","claim":"HARVARD BIOSCIENCE INC reported the fourth quarter and year ended December 31, 2022 results: revenue $28.4 million, net income $(1.7) M, EPS $(0.04).","evidence_excerpt":"Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and year ended December 31, 2022. Our fourth quarter revenues were $28.4 million, down 14% versus the comparable prior year period, including a negative currency impact of $1.0 million. During the quarter ended December 31, 2022, our cellular and molecular","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1123494/000117184323001518/0001171843-23-001518-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2022"},{"label":"Revenue","value":"$28.4 million"},{"label":"Net income","value":"$(1.7) M"},{"label":"EPS","value":"$(0.04)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}